Sai Life
Sai Life Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Sai Life Sciences projects a **long-term revenue growth guidance of 15% to 20%** over a 3-to-5-year horizon. Sai Life Sciences projects mid-term revenue growth of **15% to 20%** over a 3-5 year period, emphasizing a longer-term view due to industry lumpiness.
From Sai Life's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Sai Life Sciences projects a **long-term revenue growth guidance of 15% to 20%** over a 3-to-5-year horizon.
- The company reported a **30% annualized growth** last year, indicating strong momentum.
- Growth is expected despite inherent business lumpiness, with a plan to **balance capacity expansion and technology investment**.
- The CDMO business anticipates **better performance in the second half of FY27**, driven by new capacity coming online.
- Expanded collaborations via **dedicated FTE development contracts** and integrated service models with large pharma are expected to deepen customer relationships and pipeline.
- Strategic investments, including significant capex (~INR 1,100-1,300 crores for FY27), aim to build capabilities in peptides and other modalities for sustained growth.
- The approach focuses on building science capability before capacity to ensure value delivery over the longer term.
Profitability & Margins
See what Sai Life said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sai Life Sciences plans a capex of INR1,100 to INR1,300 crores for FY27; no guidance provided for FY28 yet.
- A significant greenfield peptide manufacturing facility near Hyderabad is planned, expected operational by 2028.
- Investment in building pilot scale conjugation facilities for ADCs is underway, spanning discovery and development stages.
- New capacity is being developed for early to mid-stage deliveries at a new greenfield manufacturing site.
- Formulation capabilities are being added, with the facility expected operational within six months, driven by customer interest.
- Expansion includes two production blocks (225 KL each) in Bidar, totaling 450 KL, with the first block on track for H2 FY27.
- Investments include flow chemistry capabilities and continuous downstream operations to handle complex molecules.
- Capex decisions are evaluated against internal hurdle rates and can be deferred if business circumstances change.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Life said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Sai Life Sciences Limited has a healthy order book supported by a growing base of large pharmaceutical customers.
- Over 90% of revenue in FY25 and FY26 came from returning customers, reflecting strong repeat orders.
- The company secured six late-phase molecules to its pipeline in the past 15 months, five of which came through large pharma clients with ongoing FTE (Full-Time Equivalent) engagements.
- Dedicated FTE development contracts are expected to augment the pipeline of late-phase and commercial molecules.
- One large pharma collaboration has expanded into a sizable dedicated FTE contract, covering the complete product lifecycle from discovery to commercial manufacturing.
- The discovery capacity expansion facility came on stream in Q1 and is already sold out, indicating strong demand.
- CDMO capacity expansion (two production blocks totaling 450 KL) is on track to come on stream by H2 FY27 to meet order commitments.
- Overall, the order pipeline is robust with continued conversion of pilot collaborations into long-term high-volume partnerships.
Sai Life — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹602 Cr, net profit ₹104 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Sai Life Q1 FY27 results?
Sai Life Sciences projects a **long-term revenue growth guidance of 15% to 20%** over a 3-to-5-year horizon. Sai Life Sciences projects mid-term revenue growth of **15% to 20%** over a 3-5 year period, emphasizing a longer-term view due to industry lumpiness.
What is Sai Life share price analysis?
Sai Life currently shows a below-average growth signal. The stock trades at a P/E of 84.1 with a market cap of ₹30,940 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Life planning capital expenditure?
Sai Life Sciences plans a capex of INR1,100 to INR1,300 crores for FY27; no guidance provided for FY28 yet.
Keep Sai Life on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.